108 related articles for article (PubMed ID: 28215510)
1. Short-term treatment with flumazenil restores long-term object memory in a mouse model of Down syndrome.
Colas D; Chuluun B; Garner CC; Heller HC
Neurobiol Learn Mem; 2017 Apr; 140():11-16. PubMed ID: 28215510
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.
Colas D; Chuluun B; Warrier D; Blank M; Wetmore DZ; Buckmaster P; Garner CC; Heller HC
Br J Pharmacol; 2013 Jul; 169(5):963-73. PubMed ID: 23489250
[TBL] [Abstract][Full Text] [Related]
3. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down's syndrome.
Andrade-Talavera Y; Benito I; Casañas JJ; Rodríguez-Moreno A; Montesinos ML
Neurobiol Dis; 2015 Oct; 82():516-525. PubMed ID: 26388397
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABA
Duchon A; Gruart A; Albac C; Delatour B; Zorrilla de San Martin J; Delgado-García JM; Hérault Y; Potier MC
Br J Pharmacol; 2020 Mar; 177(5):1106-1118. PubMed ID: 31652355
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome.
Begenisic T; Baroncelli L; Sansevero G; Milanese M; Bonifacino T; Bonanno G; Cioni G; Maffei L; Sale A
Neurobiol Dis; 2014 Mar; 63():12-9. PubMed ID: 24269730
[TBL] [Abstract][Full Text] [Related]
9. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
Heinen M; Hettich MM; Ryan DP; Schnell S; Paesler K; Ehninger D
Neural Plast; 2012; 2012():467251. PubMed ID: 22848851
[TBL] [Abstract][Full Text] [Related]
10. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.
Deidda G; Parrini M; Naskar S; Bozarth IF; Contestabile A; Cancedda L
Nat Med; 2015 Apr; 21(4):318-26. PubMed ID: 25774849
[TBL] [Abstract][Full Text] [Related]
11. Object recognition memory is conserved in Ts1Cje, a mouse model of Down syndrome.
Fernandez F; Garner CC
Neurosci Lett; 2007 Jun; 421(2):137-41. PubMed ID: 17566652
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
[TBL] [Abstract][Full Text] [Related]
14. Designer receptors enhance memory in a mouse model of Down syndrome.
Fortress AM; Hamlett ED; Vazey EM; Aston-Jones G; Cass WA; Boger HA; Granholm AC
J Neurosci; 2015 Jan; 35(4):1343-53. PubMed ID: 25632113
[TBL] [Abstract][Full Text] [Related]
15. Flumazenil administration attenuates cognitive impairment in immature rats after controlled cortical impact.
Ochalski PG; Fellows-Mayle W; Hsieh LB; Srinivas R; Okonkwo DO; Dixon CE; Adelson PD
J Neurotrauma; 2010 Mar; 27(3):647-51. PubMed ID: 19929186
[TBL] [Abstract][Full Text] [Related]
16. The legacy of the benzodiazepine receptor: from flumazenil to enhancing cognition in Down syndrome and social interaction in autism.
Möhler H
Adv Pharmacol; 2015; 72():1-36. PubMed ID: 25600365
[TBL] [Abstract][Full Text] [Related]
17. Flumazenil but not bicuculline counteract the impairing effects of anesthetic ketamine on recognition memory in rats. Evidence for a functional interaction between the GABA
Lafioniatis A; Bermperian VC; Pitsikas N
Neuropharmacology; 2019 Apr; 148():87-95. PubMed ID: 30597159
[TBL] [Abstract][Full Text] [Related]
18. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
[TBL] [Abstract][Full Text] [Related]
19. Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.
Lysenko LV; Kim J; Henry C; Tyrtyshnaia A; Kohnz RA; Madamba F; Simon GM; Kleschevnikova NE; Nomura DK; Ezekowitz RA; Kleschevnikov AM
PLoS One; 2014; 9(12):e114521. PubMed ID: 25474204
[TBL] [Abstract][Full Text] [Related]
20. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome.
Di Filippo M; Tozzi A; Ghiglieri V; Picconi B; Costa C; Cipriani S; Tantucci M; Belcastro V; Calabresi P
Biol Psychiatry; 2010 Apr; 67(7):666-71. PubMed ID: 19818432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
